Induced Pluripotent Stem Cells for Primary Ciliary Dyskinesia Modeling and Personalized Medicine

Am J Respir Cell Mol Biol. 2018 Dec;59(6):672-683. doi: 10.1165/rcmb.2018-0213TR.


Primary ciliary dyskinesia (PCD) is a rare and heterogeneous genetic disorder that affects the structure and function of motile cilia. In the airway epithelium, impaired ciliary motion results in reduced or absent mucociliary clearance that leads to the appearance of chronic airway infection, sinusitis, and bronchiectasis. Currently, there is no effective treatment for PCD, and research is limited by the lack of convenient models to study this disease and investigate innovative therapies. Furthermore, the high heterogeneity of PCD genotypes is likely to hinder the development of a single therapy for all patients. The generation of patient-derived, induced pluripotent stem cells, and their differentiation into airway epithelium, as well as genome editing technologies, could represent major tools for in vitro PCD modeling and for developing personalized therapies. Here, we review PCD pathogenesis and then discuss how human induced pluripotent stem cells could be used to model this disease for the development of innovative, patient-specific biotherapies.

Keywords: PCD; airway epithelium; cilia; iPSC; therapy.

Publication types

  • Review

MeSH terms

  • Cell- and Tissue-Based Therapy*
  • Ciliary Motility Disorders / pathology*
  • Ciliary Motility Disorders / therapy*
  • Humans
  • Induced Pluripotent Stem Cells / cytology*
  • Precision Medicine*